China CAR-T Front-Runner Allegations Reveal Soft Underbelly Of Development Race

 
• By Brian Yang

A report from a short-seller group accuses Chinese firm Nanjing Legend of intentionally omitting clinical data for its CAR-T candidate, an allegation the company has refuted while global partner J&J says it remains "optimistic" about the product and conducted "careful" reviews of the data.

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment
Report Claims Nanjing Legend Used Selected Data For CAR-T Asset Licensed To Janssen

More from China

More from Focus On Asia